Co-Authors
This is a "connection" page, showing publications co-authored by Lesley Scott and Ian Sanne.
Connection Strength
1,029
-
Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting. J Clin Microbiol. 2018 12; 56(12).
Score: 0,160
-
Multidisciplinary Point-of-Care Testing in South African Primary Health Care Clinics Accelerates HIV ART Initiation but Does Not Alter Retention in Care. J Acquir Immune Defic Syndr. 2017 09 01; 76(1):65-73.
Score: 0,147
-
Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa. Int J Tuberc Lung Dis. 2013 Mar; 17(3):368-72.
Score: 0,108
-
Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med. 2011 Jul; 8(7):e1001061.
Score: 0,096
-
Performance of the Abbott SARS-CoV-2 IgG serological assay in South African 2 patients. PLoS One. 2022; 17(2):e0262442.
Score: 0,050
-
Operational characteristics of 30 lateral flow immunoassays used to identify COVID-19 immune response. J Immunol Methods. 2021 09; 496:113096.
Score: 0,048
-
Performance of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies in South Africa. PLoS One. 2021; 16(6):e0252317.
Score: 0,048
-
SARS-CoV-2 Antigens Expressed in Plants Detect Antibody Responses in COVID-19 Patients. Front Plant Sci. 2021; 12:589940.
Score: 0,047
-
The role of serological testing in the SARS-CoV-2 outbreak. S Afr Med J. 2020 07 17; 110(9):842-845.
Score: 0,045
-
Continuous quality monitoring in the field: an evaluation of the performance of the Fio Deki Reader™ for rapid HIV testing in South Africa. BMC Infect Dis. 2020 May 04; 20(1):320.
Score: 0,044
-
Implementation and Operational Research: Implementation of Multiple Point-of-Care Testing in 2 HIV Antiretroviral Treatment Clinics in South Africa. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):e34-43.
Score: 0,033
-
The patient impact of point-of-care vs. laboratory placement of Xpert(®) MTB/RIF. Int J Tuberc Lung Dis. 2015 Jul; 19(7):811-6.
Score: 0,032
-
Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respir Crit Care Med. 2014 Jun 01; 189(11):1426-34.
Score: 0,029
-
Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One. 2013; 8(6):e65421.
Score: 0,027
-
Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis. Eur J Clin Microbiol Infect Dis. 2013 Nov; 32(11):1409-15.
Score: 0,027
-
Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J. 2012 Sep 07; 102(10):805-7.
Score: 0,026
-
Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn. 2010 Oct; 10(7):937-46.
Score: 0,023
-
Large-scale affordable PanLeucogated CD4+ testing with proactive internal and external quality assessment: in support of the South African national comprehensive care, treatment and management programme for HIV and AIDS. Cytometry B Clin Cytom. 2008; 74 Suppl 1:S40-51.
Score: 0,019
-
CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort. Cytometry B Clin Cytom. 2008; 74 Suppl 1:S131-40.
Score: 0,019